Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.
about
Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature reviewAdvances of heterogeneity of EGFR in non-small cell lung cancerTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesMolecular pathology of non-small cell lung cancer: a practical guide.Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?Molecular testing guidelines for lung adenocarcinoma: Utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples.Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour.Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR.Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasisALKBH3, a human AlkB homologue, contributes to cell survival in human non-small-cell lung cancer.Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells.Tumour heterogeneity in the clinic.EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastasesComparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas.Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice.Efficacy of surgical treatment for brain metastasis in patients with non-small cell lung cancerA robust method to analyze copy number alterations of less than 100 kb in single cells using oligonucleotide array CGH.Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer.Epidermal growth factor receptor mutations in colorectal cancer patientsRadiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical studySULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15.Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and PrognosisEGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.LDA-SVM-based EGFR mutation model for NSCLC brain metastases: an observational study.EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).Assessment of prognostic scores of brain metastases from lung adenocarcinoma with EGFR mutations.Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications.Clinical outcome of epidermal growth factor receptor-tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutationsCancer genes in lung cancer: racial disparities: are there any?Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trialsFrom targets to targeted therapies and molecular profiling in non-small cell lung carcinoma.Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis.Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancerDiscordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain MetastasisEfficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma.High concordance of ALK rearrangement between primary tumor and paired metastatic lymph node in patients with lung adenocarcinoma.EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patientsDiffering deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant.
P2860
Q26785713-52DA8147-1850-44AC-8517-BF68564A395DQ26999714-104614AE-58C6-4E34-84E0-DE457F832FABQ27014117-E23A38E2-1DD2-49EC-93CA-C84E8ADAB543Q27690919-1B23E214-8F7B-4283-A083-A0A5F80684CAQ33407582-FAFE9A63-E6C0-43BD-9FB4-1FEE9C63C82FQ33700689-85E753DE-82F0-4092-B286-E9DE4C9328C9Q33760283-2FEB31BC-C4B0-41A8-BD20-32D7C30B9300Q33793611-E75DA83E-D34B-4998-9E82-B6E6660C6E79Q33847505-851BD3D7-E1B5-4D0E-A2B9-BF3429851D82Q33947318-634CB40C-8929-4C9D-869D-2478730C37E2Q34162084-664B3924-CA66-4F2E-BE81-A3A5C0DD57D6Q34231456-6E26C749-18A7-49C0-A2E2-3F0C3C414C13Q34372080-ED19BB36-54C9-4E6D-89F8-D2D10450F876Q34461771-90D17173-AE27-4FC5-86BB-63C6FB3C3173Q34567984-53F52512-C8CD-40E1-85BE-D3E3ABB800CEQ34756451-A4FD8D8E-33D2-48E2-8925-99399193C79EQ34774082-6104B227-702D-4EF5-A912-E3D34535694CQ34794604-C3C5D6D0-98BC-413C-9130-25FBABE571CBQ34996167-FE29E79B-F9FC-408C-B6C2-040D85FF1C0EQ35134625-23B35FEE-B2D3-4172-B604-22FBB1BC5760Q35814752-3504F216-DF3E-4FFB-8C82-DA836687B20BQ35840419-221AF769-1440-4E68-8406-E67270CED7ACQ35954518-A37BF52A-4EA2-4668-9C5D-8906676F16A9Q36044399-B88150ED-6826-400A-B625-7C4E1C957F7DQ36102842-023558E8-E1CD-441F-84BB-6FF76495E119Q36152207-12E020A6-F683-4296-B108-6AB28F8A1DABQ36250691-FC829C4D-CBEB-4A0F-9A74-A38276843B3BQ36341131-6F91F4B2-27C9-4C13-9365-1B458326FC72Q36475875-49682DE2-CEB8-4684-8486-5DAE2257A934Q36477762-E88BC1F1-7DF5-4B0A-AE42-207C86808F8FQ36481954-D78D27AD-E3AF-413B-ACB0-4CEA6CF9A395Q36493048-8B86CF14-5C80-4A0C-9CAA-2EF2C58F1785Q36615755-EDF65FEE-50B7-4549-9043-65A698D5CD20Q36684011-A246F5B6-520D-4557-8B65-D0EA088B283BQ36834504-082B9C00-75C4-4467-B7E1-A5DFBC159576Q36847104-90FA5555-4A45-40C4-9CF8-C1E9869BE4F0Q36924484-CA04F8F2-98CE-4A4F-BDBD-669E2403FEAAQ36948934-9A083290-F030-458E-B22A-939B74EAEA5FQ36977414-B564F5B1-A102-473D-AF42-FE172356DCAAQ37160656-EB627276-6D33-4F51-84D1-B320BF31D718
P2860
Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Comparison of EGFR and K-RAS g ...... esponding metastases in NSCLC.
@en
type
label
Comparison of EGFR and K-RAS g ...... esponding metastases in NSCLC.
@en
prefLabel
Comparison of EGFR and K-RAS g ...... esponding metastases in NSCLC.
@en
P2093
P2860
P356
P1476
Comparison of EGFR and K-RAS g ...... esponding metastases in NSCLC.
@en
P2093
A Kalikaki
A Koutsopoulos
A Voutsina
D Mavroudis
E Stathopoulos
J Souglakos
V Georgoulias
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604629
P407
P577
2008-09-01T00:00:00Z